Focused ultrasound treatment for tremor in Parkinson's disease, and why tremor may return
Studies focused ultrasound thalamotomy for tremor in people with Parkinson's disease, followed for 24 months.
Plain-language title generated from the registry record
Registry title: MRgFUS for Parkinson's Tremor
Key facts
- Where
- Aarhus, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT07284719, who can take part
Where in Denmark
- Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aarhus University Hospital
- Trial code
- NCT07284719
- Record updated
- 7 January 2026
- Original description
This study investigates magnetic resonance-guided focused ultrasound thalamotomy (MRgFUSth) for people with Parkinson's disease (PD) and tremor not responding to conventional standard doses of dopamine replacement therapy. The aim is to identify clinical and imaging biomarkers predictive of sustained tremor control up to 24 months after MRgFUSth treatment. Participants will undergo a suprathreshold levodopa test and ¹⁸F-DOPA PET imaging to evaluate dopaminergic and serotonergic involvement in tremor. All participants will receive MRgFUSth and be followed for 24 months with standardized clinical, cognitive, and quality-of-life assessments. The study seeks to improve understanding the possible mechanisms of tremor relapse and inform patient selection for MRgFUSth in PD.Read full original descriptionShow less
Predictors and Mechanisms of Tremor Relapse After MR-Guided Focused Ultrasound Thalamotomy in Parkinson's Disease
This study investigates magnetic resonance-guided focused ultrasound thalamotomy (MRgFUSth) for people with Parkinson's disease (PD) and tremor not responding to conventional standard doses of dopamine replacement therapy. The aim is to identify clinical and imaging biomarkers predictive of sustained tremor control up to 24 months after MRgFUSth treatment. Participants will undergo a suprathreshold levodopa test and ¹⁸F-DOPA PET imaging to evaluate dopaminergic and serotonergic involvement in tremor. All participants will receive MRgFUSth and be followed for 24 months with standardized clinical, cognitive, and quality-of-life assessments. The study seeks to improve understanding the possible mechanisms of tremor relapse and inform patient selection for MRgFUSth in PD.
Inclusion: Established diagnosis of idiopathic Parkinson's disease; Tremor not manageable with optimal medication; Clinical Indication for MRgFUSth; Able to understand study requirements and provide consent; HOEHN and YAHR <3.
Exclusion: Active drug abuse; Dementia or severe cognitive impairment; The presence of another significant neurological/psychiatric disorder or significant disease; Epilepsy; History of stroke or structural lesions on MRI that could interfere with image analysis; Cardiac pacemaker; Patients who do not want information about findings of unknown disease during the trial; Severe psychopathology, not medically managed; Poor balance and gait function based on neurological examination; Contraindications for MRI; Pregnancy or breast-feeding; Claustrophobia; Patients unable to lie on the back for 2-4 hours in the MR-scanner-setting; SDR (Skull density rate) lower than 0.35.